Mark Stenhouse
CIK: 0001734751
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
PHAT
Phathom Pharmaceuticals, Inc.
Director
Discretionary Trading P&L
Holdings
About Stenhouse Mark
Stenhouse Mark (SEC CIK 0001734751) files insider reports with the SEC as Director of Phathom Pharmaceuticals, Inc. (PHAT).
Signal8 holds 2 ownership filings by Stenhouse Mark, all Form 4s, filed between Jun 5, 2025 and May 21, 2026. Those filings report 2 transactions, from Jun 3, 2025 to May 19, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Stenhouse Mark's filings is in FLORHAM PAK, NJ.
Recent filings by Stenhouse Mark
Other insiders filing for Phathom Pharmaceuticals, Inc. (PHAT)
- Narula Sanjeev, Chief Financial & Bus. Officer
- Breedlove Robert Charles, Principal Accounting Officer
- Parikh Asit, Director
- Topper James N, Director
- FIELDS HEIDI, Director
- COLA MICHAEL F, Director